Have a feature idea you'd love to see implemented?
Let us know!
TVTX Travere Therapeutics Inc
Price (delayed)
$18.26
Market cap
$1.43B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.58
Enterprise value
$1.79B
Travere Therapeutics is a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this
Highlights
Travere Therapeutics's gross profit has surged by 59% YoY and by 15% QoQ
The revenue has surged by 57% year-on-year and by 15% since the previous quarter
TVTX's net income has dropped by 141% since the previous quarter
The company's EPS has shrunk by 140% QoQ
Key stats
What are the main financial stats of TVTX
Market
Valuations
Earnings
Shares outstanding
78.05M
Market cap
$1.43B
Enterprise value
$1.79B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
6.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.8
Revenue
$203.45M
EBIT
-$340.01M
EBITDA
-$299.06M
Free cash flow
-$304.41M
Per share
Balance sheet
Liquidity
EPS
-$4.58
Free cash flow per share
-$3.91
Book value per share
-$0.4
Revenue per share
$2.62
TBVPS
$5.15
Total assets
$504.41M
Total liabilities
$534.86M
Debt
$402.43M
Equity
-$30.45M
Working capital
$134.7M
Debt to equity
-13.21
Current ratio
1.71
Quick ratio
1.59
Net debt/EBITDA
-1.22
Margins
Efficiency
Dividend
EBITDA margin
-147%
Gross margin
95.2%
Net margin
-172.7%
Operating margin
-175.6%
Return on assets
-56.1%
Return on equity
-541.6%
Return on invested capital
-47.3%
Return on capital employed
-108.2%
Return on sales
-167.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TVTX stock price
How has the Travere Therapeutics stock price performed over time
Intraday
2.24%
1 week
-1.14%
1 month
0.88%
1 year
223.19%
YTD
103.11%
QTD
30.52%
Financial performance
How have Travere Therapeutics's revenue and profit performed over time
Revenue
$203.45M
Gross profit
$193.69M
Operating income
-$357.32M
Net income
-$351.45M
Gross margin
95.2%
Net margin
-172.7%
The net margin has dropped by 157% year-on-year and by 110% since the previous quarter
TVTX's net income has dropped by 141% since the previous quarter
Travere Therapeutics's gross profit has surged by 59% YoY and by 15% QoQ
The revenue has surged by 57% year-on-year and by 15% since the previous quarter
Growth
What is Travere Therapeutics's growth rate over time
Valuation
What is Travere Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
6.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.8
The company's EPS has shrunk by 140% QoQ
TVTX's equity has dropped by 111% year-on-year
The stock's P/S is 62% above its last 4 quarters average of 4.3 but 8% below its 5-year quarterly average of 7.6
The revenue has surged by 57% year-on-year and by 15% since the previous quarter
Efficiency
How efficient is Travere Therapeutics business performance
The company's return on sales has shrunk by 187% YoY and by 121% QoQ
The return on invested capital has dropped by 177% since the previous quarter
The company's return on assets has shrunk by 172% QoQ
Dividends
What is TVTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TVTX.
Financial health
How did Travere Therapeutics financials performed over time
TVTX's total assets is 6% less than its total liabilities
The quick ratio has plunged by 66% YoY and by 45% from the previous quarter
The company's current ratio has shrunk by 65% YoY and by 44% QoQ
Travere Therapeutics's debt to equity has plunged by 150% from the previous quarter
TVTX's equity has dropped by 111% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.